<DOC>
	<DOCNO>NCT00982735</DOCNO>
	<brief_summary>The `` CONTROL '' study patient base prospective observational cohort study . The main aim study survey safety efficacy Micardis 40 mg/day 80 mg/day real life condition usual clinical practice essential hypertensive patient Kingdom Saudi Arabia . The patient participate study survey 24 week .</brief_summary>
	<brief_title>An Observational Cohort Study Evaluate Safety Efficacy Micardis Tablets Taken Once Daily 40 mg/Day 80 mg/Day Hypertensive Patients Under Real Life Conditions Usual Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Male female . Aged 20 80 year old . Adult essential hypertensive either newly diagnose untreated , previously treat uncontrolled patient ; sit blood pressure : systolic BP &gt; 140 mmHg &lt; 180 mmHg , and/or diastolic BP &gt; 90 mmHg &lt; 110 mmHg ) . Patients assessed benefit intake angiotensin II receptor blocker ( ARB ) monotherapy addon medication . Patients contraindication telmisartan use ( per Micardis® Tablets package insert ) . Known hypersensitivity active ingredient excipients Micardis® Tablets . Any clinical condition , opinion attend physician , would allow safe administration study medication . Patients participate protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>